Sharing clinical trial data : maximizing benefits, minimizing risk
Author(s)
Bibliographic Information
Sharing clinical trial data : maximizing benefits, minimizing risk
National Academies Press, c2015
Available at 1 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references
Description and Table of Contents
Description
Data sharing can accelerate new discoveries by avoiding duplicative trials, stimulating new ideas for research, and enabling the maximal scientific knowledge and benefits to be gained from the efforts of clinical trial participants and investigators. At the same time, sharing clinical trial data presents risks, burdens, and challenges. These include the need to protect the privacy and honor the consent of clinical trial participants; safeguard the legitimate economic interests of sponsors; and guard against invalid secondary analyses, which could undermine trust in clinical trials or otherwise harm public health.
Sharing Clinical Trial Data presents activities and strategies for the responsible sharing of clinical trial data. With the goal of increasing scientific knowledge to lead to better therapies for patients, this book identifies guiding principles and makes recommendations to maximize the benefits and minimize risks. This report offers guidance on the types of clinical trial data available at different points in the process, the points in the process at which each type of data should be shared, methods for sharing data, what groups should have access to data, and future knowledge and infrastructure needs.
Responsible sharing of clinical trial data will allow other investigators to replicate published findings and carry out additional analyses, strengthen the evidence base for regulatory and clinical decisions, and increase the scientific knowledge gained from investments by the funders of clinical trials. The recommendations of Sharing Clinical Trial Data will be useful both now and well into the future as improved sharing of data leads to a stronger evidence base for treatment. This book will be of interest to stakeholders across the spectrum of research-from funders, to researchers, to journals, to physicians, and ultimately, to patients.
Table of Contents
Front Matter
Summary
1 Introduction
2 Guiding Principles for Sharing Clinical Trial Data
3 The Roles and Responsibilities of Stakeholders in the Sharing of
Clinical Trial Data
4 The Clinical Trial Life Cycle and When to Share Data
5 Access to Clinical Trial Data: Governance
6 The Future of Data Sharing in a Changing Landscape
Appendix A: Study Approach
Appendix B: Concepts and Methods for De-identifying Clinical Trial
Data
Appendix C: Legal Discussion of Risks to Industry Sponsors
Appendix D: Clinical Trial Data Sharing Policies: Top 1-12
Pharmaceutical Companies Ranked by 2013 Market Capitalization
Appendix E: Biosketches of Committee Members
Table of Contents
- 1 Front Matter
- 2 Summary
- 3 1 Introduction
- 4 2 Guiding Principles for Sharing Clinical Trial Data
- 5 3 The Roles and Responsibilities of Stakeholders in the Sharing of Clinical Trial Data
- 6 4 The Clinical Trial Life Cycle and When to Share Data
- 7 5 Access to Clinical Trial Data: Governance
- 8 6 The Future of Data Sharing in a Changing Landscape
- 9 Appendix A: Study Approach
- 10 Appendix B: Concepts and Methods for De-identifying Clinical Trial Data
- 11 Appendix C: Legal Discussion of Risks to Industry Sponsors
- 12 Appendix D: Clinical Trial Data Sharing Policies: Top 1-12 Pharmaceutical Companies Ranked by 2013 Market Capitalization
- 13 Appendix E: Biosketches of Committee Members
by "Nielsen BookData"